Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Halozyme Therapeutics (NASDAQ:HALO) had its price target increased by investment analysts at Wells Fargo & Company from $95.00 to $110.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of 6.15% from the stock’s current price.

A number of other equities analysts also recently issued reports on HALO. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. JPMorgan Chase & Co. boosted their price objective on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Tuesday, November 3rd. Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $106.09.

Halozyme Therapeutics Trading Down 15.7%

Shares of HALO stock opened at $103.63 on Friday. The business’s 50 day moving average is $115.19 and its two-hundred day moving average is $84.73. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $134.00. The company has a market capitalization of $11.76 billion, a P/E ratio of 26.37, a price-to-earnings-growth ratio of 0.39 and a beta of 0.92. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to analysts’ expectations of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 488.26%. The firm’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.72 earnings per share. Equities analysts forecast that Halozyme Therapeutics will post 8.32 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 18,996 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the transaction, the director owned 58,839 shares of the company’s stock, valued at $6,339,313.86. This trade represents a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 125,852 shares of company stock worth $13,538,046. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Bank of America Corp DE acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $214,504,000. William Blair Investment Management LLC acquired a new position in Halozyme Therapeutics in the second quarter worth $196,540,000. Congress Asset Management Co. boosted its holdings in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after purchasing an additional 1,052,509 shares during the period. Royal London Asset Management Ltd. boosted its holdings in Halozyme Therapeutics by 12.4% in the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after purchasing an additional 200,262 shares during the period. Finally, First Trust Advisors LP increased its stake in Halozyme Therapeutics by 46.5% during the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock valued at $95,804,000 after purchasing an additional 470,558 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.